Calidi Biotherapeutics, Inc. (CLDI) Analyst Estimates & Price Targets

Calidi Biotherapeutics, Inc. (CLDI) — Price $1.17 HealthcareBiotechnology — AMEX

Latest reported results:

Wall Street analyst estimates for Calidi Biotherapeutics, Inc. (CLDI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents.

Analyst Consensus

Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0
Total analysts2
Avg rating (1-5)1.00

Valuation Ratios

Price / Book0.53
EV / EBITDA0.09
Dividend Yield0.00%

Income Statement (10y)

Year202020212022202320242025
Revenue0$449000$45000000
Cost of Revenue0$94000$274000$1.3M0$1.7M
Gross Profit0$355000-$229000-$1.3M0-$1.7M
Research & Development$3.2M$4.7M$7.3M$13.0M$8.9M$9.7M
Selling, General & Admin$3.6M$6.2M$15.6M$16.0M$12.9M$10.5M
Operating Expenses$6.8M$10.8M$22.9M$27.7M$21.8M$18.6M
Operating Income-$6.8M-$10.5M-$23.1M-$29.0M-$21.8M-$20.2M
EBITDA-$6.7M-$9.4M-$25.0M-$24.2M-$19.7M-$18.2M
Interest Expense$163000$614000$158000$3.7M$933000$207000
Pre-tax Income-$7.9M$3.4M-$25.4M-$29.2M-$22.2M-$20.0M
Income Tax$4000$11000$11000$16000$14000$15000
Net Income-$7.9M-$10.9M-$25.4M-$29.2M-$22.1M-$19.9M
EPS$-42.24$226.56$-5740.80$-3321.76$-571.20$-95.20
EPS (Diluted)$-42.24$226.56$-5740.80$-3321.76$-571.20$-95.20
Shares Outstanding (Diluted)$186265$14914$4412$8760$41526$268875

Price

Price$1.17
Market Cap$1M
ExchangeAMEX
CountryUS

Related companies: CANF · CMND · CNSP · KZIA · QLGN · SILO · SNGX

Explore sector: Healthcare · Biotechnology

More sections of CLDI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks